Rift-lines within european regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and / Libristo.pl
Rift-lines within european regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and

Kod: 07036911

Rift-lines within european regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and

Autor Malik Osmane

Biopharmaceutical medicinal products (biologics) represent a huge financial market. Thus upon patent protection expiry of the innovator (reference) biologic there is interest from industry to gain a portion of this market by launc ... więcej

895.97


Dostępna u dostawcy
Wysyłamy za 14 - 18 dni
Dodaj do schowka

Zobacz książki o podobnej tematyce

Podaruj tę książkę jeszcze dziś
  1. Zamów książkę i wybierz "Wyślij jako prezent".
  2. Natychmiast wyślemy Ci bon podarunkowy, który możesz przekazać adresatowi prezentu.
  3. Książka zostanie wysłana do adresata, a Ty o nic nie musisz się martwić.

Dowiedz się więcej

Więcej informacji o Rift-lines within european regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and

Za ten zakup dostaniesz 525 punkty

Opis

Biopharmaceutical medicinal products (biologics) represent a huge financial market. Thus upon patent protection expiry of the innovator (reference) biologic there is interest from industry to gain a portion of this market by launching a 'similar' biologic at a reduced development cost, thus boosting potential gains. The EMA responded to this desire and lead the guidance process with industry on the topic of biosimilars. Based on the experience gained with biosimilars in the past, the EMA started to introduce a second generation series of guidance documents, which take into account the past, current and possibly future challenges of biosimilars. Those proposals were evaluated by EMA and partially incorporated into new guidance documents. This work highlights the challenges and risks associated with biosimilar submissions for large and complex bio-molecules such antibodies. Results: There are unaddressed questions for the regulator with regard to the unsolved dynamic of heterogeneity and variations of the quality profile, which have potential implications on safety and efficacy. This is neglected and not taken into account seriously enough by the stakeholders. Solution: Further, the only (in my view) progressive way to deal with such foreseeable situations from the biosimilar developer's point of view is to incorporate a design space.

Szczegóły książki

Kategoria Książki po angielsku Medicine Nursing & ancillary services Pharmacy / dispensing

895.97

Ulubione w innej kategorii


250 000
zadowolonych klientów

Od roku 2008 obsłużyliśmy wielu miłośników książek, ale dla nas każdy był tym wyjątkowym.


Paczkomat 12,99 ZŁ 31975 punktów

Copyright! ©2008-24 libristo.pl Wszelkie prawa zastrzeżonePrywatnieCookies


Konto: Logowanie
Wszystkie książki świata w jednym miejscu. I co więcej w super cenach.

Koszyk ( pusty )

Kup za 299 zł i
zyskaj darmową dostawę.

Twoja lokalizacja: